ClinicalTrials.gg
CompletedNCT01439009Updated Oct 22, 2019Results posted

Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

A Phase 4 interventional study of Tolvaptan and Placebo of tolvaptan in Heart Failure, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-10-22.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
8th of 19
100 · median 60
Started
2011
with 1 other
Phase 4
9 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
3 of 19
Otsuka Pharmaceutical Co., Ltd.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 8th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 4, and was the 8th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as loop diuretics in order to investigate the effect of tolvaptan on the mid- to long-term prognosis of the target population. The efficacy of tolvaptan during the treatment period will also be investigated.

03

Conditions studied

  • Heart Failure

Keywords

  • Heart failure
  • Volume overload
  • Tolvaptan
  • loop diuretics
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from whom has been properly obtained in writing prior to start of the trial
  • Patients who have been clinically diagnosed with heart failure
  • Patients with any of the following conditions or symptoms: lower limb edema, dyspnea, jugular venous distension, hepatomegaly, pulmonary rales, third heart sound, or pulmonary congestion
  • Patients who have been receiving loop diuretics, thiazide diuretics, or anti-aldosterone diuretics
  • Male or female patients of age 20 to 85 years inclusive (at time of informed consent)
  • Patients who, together with their partner(s), are able to use an appropriate method of until 3 months after final trial drug administration
  • Patients who are able to be hospitalized at the trial site for at least 7 days from the start of trial drug administration

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of to any ingredient of the drug or to tolvaptan analogues (e.g., mozavaptan hydrochloride)
  • Patients with anuria
  • Patients who cannot sense thirst or who have difficulty with fluid intake
  • Patients with hypernatremia (serum sodium concentration > institutional ) 5) Female patients who are pregnant, possibly pregnant, or nursing
  • Patients judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial due to any of the following conditions or symptoms:

    • Hyponatremia (serum sodium concentration \< 125 mEq/L)
    • Serious coronary artery disease or cerebrovascular disease
    • Hyperkalemia
    • Severe renal disorder
    • Poorly controlled diabetes mellitus
    • Severe hepatic disease
    • Impaired urinary excretion due to urinary stenosis, calculus, or tumor
    • Cardiac valve disease with significant heart valve stenosis
    • Malignant tumor of unfavorable prognosis
  • Patients with suspected hypovolemia
  • Patients with an implanted circulatory support device
  • Patients in whom acute cardiac infarction occurred within 30 days prior to the screening examination
  • Patients who participated in any other clinical trial or postmarketing clinical trial within 30 days prior to the date of for the present trial
  • Patients who received tolvaptan within 26 weeks prior to the date of informed consent
  • Patients who are otherwise judged by the investigator or sub-investigator to be inappropriate for inclusion in the trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Tolvaptan

    15 mg

    Drug: Tolvaptan

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo of tolvaptan

Interventions

  • Once-daily oral administration of one tolvaptan 15 mg tablet in the morning

  • DrugPlacebo of tolvaptan

    Once-daily oral administration of one placebo tablet in the morning

06

What researchers measure

Primary outcomes

  1. Cummulative Incidence of Events at Week 26

    From start day of IMP administration to final day of follow up period, 1) and 2) below were defined as event 1. Death from cardiovascular events 2. Worsening of heart failure * The day of re-hospitalization due to worsening of heart failure * The day of medication below due to worsening of heart failure Phosphodiesterase III inhibitors (Injection), Catecholamine preparations (Injection), Colforsin preparations (Injection), Diuretics (Injection), Human atrial natriuretic peptide preparations (Injection):Calperitide (Injection)

    Time frame: Week 26

  2. Mortality (Number of Death)

    Statistical comparison was not done.

    Time frame: Week26

  3. Body Weight

    The comparison of the average of amount of change from baseline. Statistical comparison was not done.

    Time frame: Day15

  4. Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade

    Of the subjects who had lower limb edema at baseline, the number of subjects whose lower limb edema severity grading. Statistical comparison was not done.

    Time frame: Day15

  5. Jugular Venous Distension

    The comparison of the average of amount of change from baseline. Statistical comparison was not done.

    Time frame: Day15

  6. Change in Liver Size From Baseline

    The comparison of the average of amount of change from baseline. Statistical comparison was not done.

    Time frame: Day15

  7. Pulmonary Rales

    Of the subjects who had pulmonary rales at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.

    Time frame: Day15

  8. Third Heart Sound

    Of the subjects who had third heart sound at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.

    Time frame: Day15

  9. Cardiothoracic Ratio

    Investigator majored Thoracic length and Cardiac length from chest X-ray. Cardiothoracic Ratio was calculated from Cardiac length/Thoracic length\*100. Lowering of Cardiothoracic Ratio suggests recovery from heart congestion. The comparison of the average of amount of change from baseline. Statistical comparison was not done.

    Time frame: Day15

  10. Pulmonary Congestion

    Of the subjects who had pulmonary congestion at baseline, the number of subjects whose pulmonary congestion severity grading showed an improvement of one grade or more (eg, moderate to mild) at completion of treatment. Statistical comparison was not done.

    Time frame: Day15

  11. Plasma Brain Natriuretic Peptide (BNP) Concentration

    The comparison of the average of amount of change from baseline. Statistical comparison was not done.

    Time frame: Day15

  12. Dypnea

    Of the subjects who had dyspnoea at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.

    Time frame: Day15

  13. Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline

    New York Heart Association (NYHA) Classification is below ClassI:No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). ClassII:Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). ClassIII:Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. ClassIV:Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

    Time frame: The day after last IMP administration and Baseline

07

Results

Posted Oct 22, 2019

Participant flow

Participant flow — Overall Study
MilestoneTolvaptanPlacebo
Started5050
Completed4247
Not completed83
Withdrew: Physician decision53
Withdrew: Protocol violation20
Withdrew: Deviation of exclusion criteria10

Outcome measures

PrimaryCummulative Incidence of Events at Week 26

From start day of IMP administration to final day of follow up period, 1) and 2) below were defined as event 1. Death from cardiovascular events 2. Worsening of heart failure * The day of re-hospitalization due to worsening of heart failure * The day of medication below due to worsening of heart failure Phosphodiesterase III inhibitors (Injection), Catecholamine preparations (Injection), Colforsin preparations (Injection), Diuretics (Injection), Human atrial natriuretic peptide preparations (Injection):Calperitide (Injection)

Time frame:
Week 26
Reported as:
Number · Percentage of events at 26 weeks
Cummulative Incidence of Events at Week 26
Percentage of events at 26 weeksTolvaptanPlacebo
Cummulative Incidence of Events at Week 2635.643.8
PrimaryMortality (Number of Death)

Statistical comparison was not done.

Time frame:
Week26
Reported as:
Number · participants
Mortality (Number of Death)
participantsTolvaptanPlacebo
Mortality (Number of Death)23
PrimaryBody Weight

The comparison of the average of amount of change from baseline. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Mean · kg
Body Weight
kgTolvaptanPlacebo
Body Weight-1.99 ± 1.61-1.20 ± 1.97
PrimaryNumber of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade

Of the subjects who had lower limb edema at baseline, the number of subjects whose lower limb edema severity grading. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Number · participants
Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade
participantsTolvaptanPlacebo
Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade2716
PrimaryJugular Venous Distension

The comparison of the average of amount of change from baseline. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Mean · cm
Jugular Venous Distension
cmTolvaptanPlacebo
Jugular Venous Distension-0.94 ± 2.07-1.23 ± 2.78
PrimaryChange in Liver Size From Baseline

The comparison of the average of amount of change from baseline. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Mean · cm
Change in Liver Size From Baseline
cmTolvaptanPlacebo
Change in Liver Size From Baseline-0.20 ± 0.52-0.19 ± 0.55
PrimaryPulmonary Rales

Of the subjects who had pulmonary rales at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Number · participants
Pulmonary Rales
participantsTolvaptanPlacebo
Pulmonary Rales139
PrimaryThird Heart Sound

Of the subjects who had third heart sound at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Number · participants
Third Heart Sound
participantsTolvaptanPlacebo
Third Heart Sound810
PrimaryCardiothoracic Ratio

Investigator majored Thoracic length and Cardiac length from chest X-ray. Cardiothoracic Ratio was calculated from Cardiac length/Thoracic length\*100. Lowering of Cardiothoracic Ratio suggests recovery from heart congestion. The comparison of the average of amount of change from baseline. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Mean · Percentage
Cardiothoracic Ratio
PercentageTolvaptanPlacebo
Cardiothoracic Ratio-2.13 ± 3.53-0.83 ± 3.85
PrimaryPulmonary Congestion

Of the subjects who had pulmonary congestion at baseline, the number of subjects whose pulmonary congestion severity grading showed an improvement of one grade or more (eg, moderate to mild) at completion of treatment. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Number · participants
Pulmonary Congestion
participantsTolvaptanPlacebo
Pulmonary Congestion2420
PrimaryPlasma Brain Natriuretic Peptide (BNP) Concentration

The comparison of the average of amount of change from baseline. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Mean · pg/mL
Plasma Brain Natriuretic Peptide (BNP) Concentration
pg/mLTolvaptanPlacebo
Plasma Brain Natriuretic Peptide (BNP) Concentration-72.60 ± 268.90-166.96 ± 353.34
PrimaryDypnea

Of the subjects who had dyspnoea at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.

Time frame:
Day15
Reported as:
Number · participants
Dypnea
participantsTolvaptanPlacebo
Dypnea1112
PrimaryNumber of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline

New York Heart Association (NYHA) Classification is below ClassI:No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). ClassII:Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). ClassIII:Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. ClassIV:Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.

Time frame:
The day after last IMP administration and Baseline
Reported as:
Number · participants
Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline
participantsTolvaptanPlacebo
Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline2224

Adverse events

Collected over 26 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan—24/50 (48%)31/50 (62%)
Placebo—22/50 (44%)7/50 (14%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTolvaptanPlacebo
Cardiac failureCardiac disorders13/5019/50
Acute Cardiac FailureCardiac disorders0/501/50
Congestive Cardiac FailureCardiac disorders1/500/50
Ventricular TachycardiaCardiac disorders0/501/50
CataractEye disorders1/500/50
Diabetic retina edemaEye disorders1/500/50
Inguinal herniaGastrointestinal disorders1/500/50
NauseaGastrointestinal disorders1/500/50
Large intestine polypGastrointestinal disorders1/500/50
FeverGeneral disorders1/500/50
Most frequent other events
Most frequent other events
EventTolvaptanPlacebo
ThirstGeneral disorders10/501/50
Blood sodium increasedInvestigations8/500/50
ConstipationGastrointestinal disorders6/502/50
ContusionInjury, poisoning and procedural complications1/503/50
Blood potassium increasedInvestigations3/501/50
HypokalaemiaMetabolism and nutrition disorders3/500/50

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TolvaptanPlaceboTotal
<=18 years000
Between 18 and 65 years91322
>=65 years413778
Age, Continuous
Age, Continuous(years)TolvaptanPlaceboTotal
Mean73.8 ± 8.471.7 ± 11.272.8 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)TolvaptanPlaceboTotal
Female211334
Male293766
Region of Enrollment
Region of Enrollment(participants)TolvaptanPlaceboTotal
Japan5050100
08

Study locations

8 sites
  • Chube Region, Japan
  • Chushikoku Region, Japan
  • Hokkaido Region, Japan
  • Hokuriku Region, Japan
  • Kansai Region, Japan
  • Kanto Region, Japan
  • Kyushu Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 22, 2011
Start
Sep 2011
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results first posted
Oct 22, 2019
Last update
Oct 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01439009
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Sep 2011
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Oct 22, 2019
Last update
Oct 22, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion